Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a ...

Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare ...

Last chance to register for our exclusive webinar, “Why Patient Perspectives Matter: Driving Success in Clinical Trials”!

Eli Lilly has partnered with insitro to advance new treatments for metabolic diseases, including metabolic ...

Johnson & Johnson’s (J&J) Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care ...

The 2024 edition of PMLiVE’s T40 list of creative agencies working on advertising, branding, creative and design projects in ...

Roche’s injectable component C5 inhibitor has been recommended by the National Institute for Health and Care Excellence (NICE) to treat the rare blood disorder paroxysmal nocturnal haemoglobinuria ...

It is hoped that preventing healthy cells from reading the molecules’ messages could lead to safer and more effective gene therapies for MND, as well as other neurodegenerative diseases, including ...

You can now start working on your entries and don’t forget to get them to us by Thursday 14 November by midnight to qualify for our early bird pricing. Entry deadline is Thursday 21 November and a ...

GSK’s Arexvy has been shown to protect older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) over three full RSV seasons. Results from the phase 3 ...

Chiesi Group has announced the operational launch of its biotech centre of excellence in Italy. The company has invested €400m to establish the facility, which it said is dedicated to developing and ...